vs
Ginkgo Bioworks Holdings, Inc.（DNA）与Pioneer Bancorp, Inc.（PBFS）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是Pioneer Bancorp, Inc.的1.3倍（$33.4M vs $25.0M），过去两年Pioneer Bancorp, Inc.的营收复合增速更高（144.9% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
先锋银行控股公司（马里兰州）是一家美国银行控股企业，为先锋银行的母公司，主要面向马里兰州本地社区用户提供零售及商业银行服务，涵盖存款账户、住房与商业抵押贷款、消费贷款及小微企业融资等产品。
DNA vs PBFS — 直观对比
营收规模更大
DNA
是对方的1.3倍
$25.0M
两年增速更快
PBFS
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $25.0M |
| 净利润 | — | $3.7M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 21.3% |
| 净利率 | — | 82.1% |
| 营收同比 | -23.8% | — |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-1.41 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAPBFS
| Q4 25 | $33.4M | $25.0M | ||
| Q3 25 | $38.8M | $24.0M | ||
| Q2 25 | $49.6M | $24.4M | ||
| Q1 25 | $48.3M | $22.8M | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $89.0M | $22.0M | ||
| Q2 24 | $56.2M | $20.9M | ||
| Q1 24 | $37.9M | $21.6M |
净利润DNAPBFS
| Q4 25 | — | $3.7M | ||
| Q3 25 | $-80.8M | $4.3M | ||
| Q2 25 | $-60.3M | $6.5M | ||
| Q1 25 | $-91.0M | $5.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.4M | $6.3M | ||
| Q2 24 | $-217.2M | $3.9M | ||
| Q1 24 | $-165.9M | $4.7M |
营业利润率DNAPBFS
| Q4 25 | -211.9% | 21.3% | ||
| Q3 25 | -231.8% | 23.4% | ||
| Q2 25 | -132.1% | 33.3% | ||
| Q1 25 | -184.1% | 32.5% | ||
| Q4 24 | -236.3% | — | ||
| Q3 24 | -62.0% | 37.2% | ||
| Q2 24 | -396.7% | 24.1% | ||
| Q1 24 | -469.1% | 28.1% |
净利率DNAPBFS
| Q4 25 | — | 82.1% | ||
| Q3 25 | -207.9% | 18.0% | ||
| Q2 25 | -121.6% | 26.4% | ||
| Q1 25 | -188.2% | 25.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -63.3% | 28.7% | ||
| Q2 24 | -386.4% | 107.4% | ||
| Q1 24 | -437.3% | 21.9% |
每股收益（稀释后）DNAPBFS
| Q4 25 | $-1.41 | $0.16 | ||
| Q3 25 | $-1.45 | $0.18 | ||
| Q2 25 | $-1.10 | $0.26 | ||
| Q1 25 | $-1.68 | $0.23 | ||
| Q4 24 | $-1.91 | — | ||
| Q3 24 | $-1.08 | $0.25 | ||
| Q2 24 | $-4.23 | $0.15 | ||
| Q1 24 | $-3.32 | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $323.9M |
| 总资产 | $1.1B | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DNAPBFS
| Q4 25 | $422.6M | — | ||
| Q3 25 | $495.5M | — | ||
| Q2 25 | $559.4M | — | ||
| Q1 25 | $325.3M | — | ||
| Q4 24 | $561.6M | — | ||
| Q3 24 | $616.2M | — | ||
| Q2 24 | $730.4M | — | ||
| Q1 24 | $840.4M | — |
股东权益DNAPBFS
| Q4 25 | $508.6M | $323.9M | ||
| Q3 25 | $559.8M | $314.2M | ||
| Q2 25 | $613.0M | $314.2M | ||
| Q1 25 | $647.4M | $310.7M | ||
| Q4 24 | $716.1M | — | ||
| Q3 24 | $797.9M | $303.8M | ||
| Q2 24 | $833.1M | $296.5M | ||
| Q1 24 | $987.3M | $289.0M |
总资产DNAPBFS
| Q4 25 | $1.1B | $2.2B | ||
| Q3 25 | $1.2B | $2.2B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.6B | — | ||
| Q1 24 | $1.6B | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $11.1M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | — |
| 自由现金流率自由现金流/营收 | -142.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 2.97× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DNAPBFS
| Q4 25 | $-47.7M | $11.1M | ||
| Q3 25 | $-31.6M | $3.9M | ||
| Q2 25 | $-40.3M | $5.1M | ||
| Q1 25 | $-51.5M | $-3.5M | ||
| Q4 24 | $-42.4M | — | ||
| Q3 24 | $-103.5M | $1.9M | ||
| Q2 24 | $-84.4M | $9.0M | ||
| Q1 24 | $-89.3M | $3.3M |
自由现金流DNAPBFS
| Q4 25 | $-47.7M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-59.1M | — | ||
| Q4 24 | $-56.1M | — | ||
| Q3 24 | $-118.6M | — | ||
| Q2 24 | $-111.4M | — | ||
| Q1 24 | $-96.0M | — |
自由现金流率DNAPBFS
| Q4 25 | -142.8% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -81.2% | — | ||
| Q1 25 | -122.4% | — | ||
| Q4 24 | -128.0% | — | ||
| Q3 24 | -133.2% | — | ||
| Q2 24 | -198.2% | — | ||
| Q1 24 | -252.9% | — |
资本支出强度DNAPBFS
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 15.8% | — | ||
| Q4 24 | 31.3% | — | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 48.1% | — | ||
| Q1 24 | 17.7% | — |
现金转化率DNAPBFS
| Q4 25 | — | 2.97× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.78× | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.30× | ||
| Q2 24 | — | 2.30× | ||
| Q1 24 | — | 0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
PBFS
暂无分部数据
